Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab and low-dose cyclosporine in severe aplastic anemia
2008-001151-22Phase 2Active
- Sponsor
- University of Naples Federico II
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of alemtuzumab in aplastic anemia, pure red cell aplasia (PRCA) and bone marrow failure, sponsored by University of Naples Federico II. Primary endpoints: Safety (adverse effects incidence), Overall survival and 2 more. Started Jun 2011; status: active.
02
Drugs
alemtuzumab
03
Conditions
aplastic anemiapure red cell aplasia (PRCA)bone marrow failure
Beyond the preview
Go deeper on 2008-001151-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001151-22.